Background: Vulvar squamous cell carcinomas (SCCs) arising in association with vulvar lichen planus (LP) are poorly documented.
and vagina, often referred to as ''lichen ruber planus.'' 1, 2 The risk of a patient developing a squamous cell carcinoma (SCC) depends on the site of involvement of LP. Although LP in extragenital skin has no cancer risk, a 5% risk has been described in oral and esophageal mucosa. 3 Recently, LP has been recognized as an associated condition in human papillomavirus (HPV)negative penile SCCs. 4, 5 In contrast, although the association of vulvar LP and SCC was reported as early as 1989, 6 the association of vulvar SCC with LP is poorly documented with either case reports only or brief mention in larger series dealing with diagnoses and treatment of vulvar LP. 1, [7] [8] [9] [10] [11] [12] Only 1 larger series reported the association of LP in 5 of 23 anogenital SCCs. 13 The risk for cancer in vulvar LP is unknown, as are the typical sites of involvement, the type of precursor lesions, and clinical characteristics of LP-associated SCC.
Vulvar SCCs can be divided according to cause into cancers induced by HPV and those arising independently of HPV 14 through precursor lesions called ''differentiated vulvar intraepithelial neoplasia'' (d-VIN), 14, 15 originally described as ''differentiated simplex in situ SCC.'' 16 The origin of HPV-negative SCCs is unclear, although mutations in the p53 gene have been suggested 17, 18 and the association of HPV-negative SCC with lichen sclerosus, a common vulvar dermatosis with a prevalence of up to 8% in gynecologic practices, 19 is well accepted. The aim of this article is to document clinical and histologic features of a large series of vulvar SCCs arising in the background of LP to elucidate possible LP-specific characteristics.
METHODS
In all, 38 patients with a primary LP-associated vulvar SCC were treated at the Department of Gynecology at the Medical University Graz, Austria, during the past 12 years. All cancers were classified according to the seventh edition of TNM classification of malignant tumors 20 : pT1a SCCs are tumors 2 cm or less in greatest diameter and with stromal invasion no greater than 1.0 mm; pT1b SCC are tumors greater 2 cm in greatest diameter or with stromal invasion greater than 1.0 mm; pT2 SCCs are tumors of any size with extension to adjacent structures (lower third urethra, lower third vagina, anus); and pT3 SCCs are tumors of any size with extension to the following structures: upper two thirds of urethra, upper two thirds of vagina, bladder mucosa, rectal mucosa, or fixed to pubic bone. Entry criteria were an unequivocal (clinical and histologic) diagnosis of LP and a minimum follow-up of 12 months, unless the end point death or recurrence occurred earlier.
LP was divided into erosive and nonerosive forms, and extent of vulvar scarring was reported. 1 LP was diagnosed clinically and confirmed histologically, following published criteria. 21 Formalinfixed and paraffin-embedded archival tissues from the Institute of Pathology at the Medical University Graz, Austria, were evaluated for HPV DNA (INNO-LiPA  HPV  Genotyping  Extra,  Innogenetics Diagnostic, Heiden, Germany). All primary and recurrent invasive SCCs and precursors were evaluated by immunohistochemistry with monoclonal antibody to p53 (clone DO-7; DAKO, Corp, Capinteria, CA) and p16 ink4a (Roche Diagnostics, Indianapolis, IN, formerly MTM Laboratories, Heidelberg, Germany), an indirect marker for a transforming infection with HPV high-risk genotypes. Institutional ethics committee approval and research study approval for this study was obtained (Medical University, EK number 20-255ex 08/09). All patients gave consent to photographic documentation.
RESULTS

I Clinical characteristics of primary LP-associated SCC
See Table I . In all, 38 women (median age 61 years at diagnosis; range 39-90 years; 9 premenopausal and 29 postmenopausal) with a primary vulvar SCC arising in nonerosive vulvar LP (n = 25) ( Fig 1, A to H ) and erosive LP (n = 13) were evaluated. The nonerosive form of LP presented either as skin-colored or white, individual or multiple papules (n = 13) ( Fig 1, A and C to F ) or larger, partly
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Lichen planus (LP) in oral and esophageal mucosa has a cancer risk of up to 5%, and LP is recognized as a risk factor for penile human papillomaviruse negative cancer. The association of vulvar LP and cancer, however, is poorly documented.
d Vulvar LP-associated human papillomavirusenegative squamous cell carcinomas are located in nonhairy vulvar mucosa, particularly in the vestibulum, have a high percentage of inguinal metastases at presentation, and have a high rate of recurrent cancer in residual diseased mucosa. The high risk for squamous cell carcinoma in vulvar mucosal LP suggests the need for regular and close monitoring. hypertrophic plaques with increased skin markings (lichenification) and varying amounts of hyperkeratosis (Fig 1, B , G, and H ). Five of 38 patients had a solitary pT1a SCC (13%), 18 of 38 patients had a solitary pT1b SCC (47%), 9 of 38 women presented with a solitary pT2 SCC (24%) (Fig 1, A to G) , and 6 of 38 women had multifocal SCCs at presentation (16%) (Fig 1, H ) . Sixteen of 38 (42%) women had inguinal lymph node metastases at presentation. There was a wide variation of vulvar architectural changes reflecting the different disease stages of LP. In early disease stages and all pT1a SCC, the vulvar anatomy was not or only mildly altered, mainly perceived as stiffening and mild or focal adhesion of labia minora and the periclitoral mucosa (Fig 1, A, D, E, and F ). Advanced LP stages were characterized by partial or complete loss of normal vulvar architecture, eg, the labia minora were partially or completely fused, the clitoris was buried, and periclitoral tissues were scarred (Fig 1, B and G to I ). Varying degrees of stenosis of the vaginal introitus were documented in 18 women (Fig 1, G and H ) . In some patients, it was therefore difficult to determine the exact anatomic location of the cancers. The primary SCCs were located in modified mucosa of clitoral hood (n = 2) (Fig 1, A) , on the labium minus (n = 5), near the clitoris (n = 8) (Fig 1, B and H ) , and in the interlabial sulcus (n = 3) (Fig 1, C ) . SCCs was located in the vestibulum in 20 patients. Thirteen of 20 vestibular SCCs were located between clitoris and urethra (Fig 1, D to F ) , 4 of 20 SCCs were located in the posterior vestibulum involving the hymen and perineum (Fig 1, G) , and 3 of 20 SCCs were located at the vestibular border facing the inner side of labium minus. All pT2 SCCs involved the entire vestibulum. The multifocal SCCs involved the vestibulum, labia minora, and periclitoral mucosa with LP separating the cancers (Fig 1, H ) . SCCs in hair-bearing vulva were not identified. Of 38 women, 27 women had no prior diagnoses of LP or had not been in regular gynecologic or dermatologic follow-up for their LP or been treated according to standard protocols when they presented with their SCC. Many patients reported a rapid development of SCC, but it was documented only in 4 women. Two women had a biopsy specimen of a LP plaque between clitoris and urethra revealing a d-VIN 4 and 5 months before a pT1a SCC was excised. The third patient with advanced LP had been in regular 6-month gynecologic control visits for 3 years when she noted a hyperkeratotic plaque 5 months after the last uneventful gynecologic visit, which was biopsied and diagnosed as SCC. The resection, performed 6 weeks later, revealed a pT1b SCC (patient 9) (Fig 1, B) . She remained free of vulvar J AM ACAD DERMATOL recurrence and metastases until she died in a car accident 11 months later. The fourth woman was in yearly follow-up for a hypertrophic LP when she presented with a pT1b SCC 11 months after the last uneventful control visit.
Treatment and clinical course of LP-associated SCC Treatment was primary chemoradiation in 2 patients, followed by subsequent surgical excision in 1 of 2 patient. Surgical excision with clear margins of at least 1 cm in 36 women left residual lesions of LP behind in all patients. All women underwent either complete inguinal lymph adenectomy or sentinel lymph node excision. In all, 21 of 38 (55%) women had no metastases and 17 of 38 (45%) women had regional LN metastases greater than 2 mm at presentation. Distant metastases (skin, pelvic lymph nodes, lung, liver) at presentation were present in 7 of 38 (18%) patients. The patient with primary chemoradiation therapy without surgery developed 4 recurrences at the site of the original SCCs, which were all resected. Fourteen of 36 (39%) women with surgical treatment developed between 1 and 5 local vulvar recurrent SCC (Fig 1, I, and Fig 2, E and G) . Five of 14 women (36%; 2 pT1b and 3 multifocal SCC) had a single recurrence (4 of 5 within 5-12 months, 1 of 5 after 41 months). Nine of 14 women (1 pT1a, 4 pT1b, 2 pT2 SCC, and 2 multifocal SCC) developed multiple recurrences. In all, 23 of 34 (68%) of all vulvar recurrent cancer and precursors occurred within 5 to 12 months (Table I) . Longer disease-free survival was associated with wider primary resections of SCC. Three of 38 patients were lost to follow-up; 19 of 38 women are presently alive with a mean follow-up of 57 months (range 12-151 months). Two of 38 women died of unrelated causes without recurrent disease and 14 of 38 (37%) women (7 pT1b, 5 pT2 SCC, 2 multifocal SCC) died of disease after a mean of 31 months (range 7-94 months) after initial diagnosis.
Histomorphologic characteristics of LP-associated SCC
The SCCs were moderately differentiated, focally keratinizing cancers, but nonkeratinizing areas were common at the invasion front. Thirty of 38 SCCs had active disease with a moderate to dense inflammatory infiltrate (Fig 2, A to C and F ). Only 8 of 38 primary SCCs had no or scant lymphocytic infiltrates. All SCCs, peritumoral intraepithelial precancerous lesions, and precursor lesions before recurrent SCC were devoid of HPV-DNA and p16 ink4a overexpression. Elongated rete ridges with basal atypia, numerous mitoses, and premature squamatization in basal and suprabasal cells with normal superficial keratinization typical of d-VIN was identified adjacent to the primary invasive SCC in 22 of 38 patients (Fig 2, E and F ) . The remaining peritumoral and recurrent precursors revealed atypical basaloid differentiation (Fig 2, G and H ) , or were flat or hypertrophic verrucous proliferations with or without hyperkeratosis. Nuclear p53 expression in invasive tumor cells (Fig 2, C and D) and in d-VIN was observed in 24 of 38 patients (67%).
DISCUSSION
To our knowledge, this is the largest series of vulvar HPV-negative SCCs associated with LP. The majority of SCCs were ulcerated large cancers. About one third of LP-associated SCCs arose in erosive LP, the remaining SCCs in papules and plaques of nonerosive forms of LP. All SCCs were located in nonhair-bearing vulvar mucosa, eg, vestibular glycogenated mucosa and modified mucosa. The vestibulum, in particular the glycogenated mucosa between clitoris and urethra, was a typical location of SCCs in our patient cohort. A group of gynecologists has described a similar location for p16 ink4a and p53-negative vulvar SCCs in younger women 22 and proposed a third type of vulvar cancer. The p53 negativity in immunohistochemical analysis and inconsistent p53 staining in HPV-negative SCCs, however, is widely recognized and these cancers belong into the HPV-negative group of vulvar cancers defined by the World Health Organization. 14 Although the authors did not comment on presence or absence of dermatoses in these patients, it is very likely that these cancers were (possibly missed) cases of LP-associated SCCs. Both clinical and histologic features of early and nonerosive forms of LP in this area are extremely subtle and often not recognized. The rarity of anogenital LP may be another contributing factor for inadequate recognition, particularly when LP is not suspected especially, which is more common in subspecialties not as familiar with the various manifestations of LP as dermatologists. Recognition of small lesions of LP lesions may require a vulvoscopic and colposcopic examination and are easier to identify in a hairless (preoperative) vulva than in a routine gynecologic practice setting. Obvious clinical findings such as the erosive and hypertrophic variants of LP were observed only in 50% of patients.
LP-associated SCCs are aggressive malignancies with a high rate of regional lymph nodes metastases at presentation and over 30% of disease-related deaths, mainly within the first 1 to 3 years. We observed a high rate of recurrent cancers in the residual diseased skin, with 68% of all recurrences Lichen planus (LP)-associated vulvar squamous cell carcinomas (SCCs). A, Ulcerated pT1b SCC (arrow) on the clitoral hood of a 40-year-old woman (patient 2) with numerous skincolored plaques of LP (arrowheads) on both labia minora, which are small and stiff, and in the right interlabial sulcus, and lichenification of periclitoral mucosa (arrowhead ). Note mild architectural changes of posterior labial adhesion. B, Periclitoral invasive pT1b SCC (arrow) with peritumoral erosion in a 52-year-old woman (patient 9) in advanced LP. The clitoris is completely buried, and both labia minora are completely fused and reveal confluent plaques of LP with increased skin markings (arrowhead). C, Primary pT1b SCC of a 70-year-old woman (patient 19) arising in the interlabial sulcus in a hypertrophic LP. D, A pT1a SCC (arrow, maximal invasion depth 0.4 mm) of a 39-year-old woman (patient 1) between clitoris and urethra. Note the numerous plaques of LP on the clitoris, periclitoral tissues, and vestibulum occurring within 5 to 12 months. The high rate of recurrent canceredespite complete removal of the cancer with a minimum margin of 1 cmeis puzzling. One possible explanation may be the trend towards minimal surgery, which removes the cancer, but leaves LP-affected skin and mucosa behind. It is conceivable that a d-VIN was already present at time of excision of the primary cancer, but not recognized clinically as a precursor lesion or mistaken as a plaque of LP. Another explanation may be that the residual LP was not adequately treated, eg, poorly controlled, suggesting that an active LP is a risk factor for recurrent SCC. The fast development of recurrent cancer supports indirectly that d-VIN is a rapidly progressing precursor lesion. The HPV-negative precursor lesions of d-VIN showed a variety of atrophic and flat lesions, but also verrucous and exophytic proliferations, and basaloid differentiation as reported before in lichen sclerosuseassociated cancers. [23] [24] [25] Criteria for d-VIN are often subtle in daily surgical practice with hematoxylin-eosinestained sections. Lack of p16 ink4a overexpression and proof of HPV negativity are helpful for a correct etiologic identification. This distinction is essential because d-VIN with a fast progression to SCC needs immediate treatment and cannot be treated expectantly or with topical immune modulators for several weeks such as HPV-induced precursors. Furthermore, our data suggest that active LP in general is at risk for malignant transformation, because the majority of our patients received no standardized treatment for their LP before development of SCC. The aim should be a reduction of lymphocytes, thus reducing tissue destruction and possibly preventing malignant transformation.
In conclusion, LP-associated SCCs are HPVnegative cancers located in glycogenated and modified vulvar mucosa, but not in hair-bearing vulvar skin. LP-associated SCCs arise via the precursor d-VIN. The aggressive SCCs have a high rate of LN metastases at initial presentation and 30% disease-related deaths. Almost 40% of patients had recurrent cancer in the residual diseased LP, mostly within the first 12 months postoperatively, which calls for close oncologic follow-up. We further propose that women with LP with or without a prior vulvar SCC need regular follow-up and appropriate treatment for control of their LP.
(arrowhead). E, A pT1b SCC (arrow, maximal invasion depth 1.4 mm) located between the clitoris and urethra in a 47-year-old-woman. Multiple plaques of LP (arrowhead) are seen around the clitoris, clitoral hood, and inner side of labia minora and vestibulum (patient 7). F, Ulcerated pT1b SCC located between urethra and clitoris of a 63-year-old woman (patient 12) with numerous individual plaques in periclitoral mucosa and interlabial sulcus. Note the stiffening of labia minora and labial fusion in the posterior aspects. G, Extensively ulcerated pT1b SCC (arrow) in the posterior vestibulum/perineum (arrowhead ) in an 88-year-old woman (patient 37). Note the numerous confluent plaques of advanced hypertrophic LP and the extensively scarred vulva with buried clitoris and loss of periclitoral tissue and labia minora. Histologic features of lichen planus (LP)-associated squamous cell carcinomas (SCCs) and precursors. A, Nonkeratinizing, human papillomavirus (HPV)-negative pT1a SCC (arrow) arising in glycogenated squamous mucosa between clitoris and urethra (patient 1 [Fig 1, D] ) with a moderate lymphohistiocytic infiltrate. B, Invasion was measured from the point of deepest invasion to the closest nontumorous epithelial rete adjacent to the SCC. C, An ulcerated, only partly keratinizing invasive pT1b SCC (patient 7). D, Reveals p53-positive invasive tumor cells and a peritumoral p53-positive intraepithelial precancerous lesion (immunohistochemistry with antibody to p53). E, A recurrent differentiated vulvar intraepithelial neoplasia (d-VIN) (arrow) arising in an area of erosive LP of patient 27. F, Shows elongation of epithelial rete, keratinocyte atypia and premature squamatization (arrow) and hyperkeratosis. Note inflammatory infiltrate. G, Recurrent d-VIN in patient 27 after excision of lesion shown in E. H, Reveals a basaloid atypical intraepithelial proliferation in hematoxylin-eosinestained section. This lesion was p16 ink4a and HPV-negative and expressed p53 on immunohistochemical analysis.
